Search
for

    Research

    5 / 844 results

    Community Join

    5 / 1000+ results

      community Will my liver get destroyed long term on this stack ??

      in Chat  15 upvotes 2 years ago
      A user is considering a long-term hair loss treatment stack including Dutasteride, Finasteride, and oral Minoxidil, and is concerned about potential liver damage. Some responses suggest the stack is excessive, while others believe it's not harmful to the liver, but recommend regular blood work to monitor health.

      community HT booked, taking finasteride and losing ground?

      in I'm Starting Treatment  1 upvotes 1 month ago
      The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

      community Bile Acid-Mediated DHT Dysregulation Hypothesis

      in Research/Science  13 upvotes 1 year ago
      Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.

      community ghk-cu is potent 5-ar inhibitor?

      in Product  9 upvotes 2 years ago
      GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.